Rare Genetic Disorders - Advancements in Diagnosis and Treatment (May 8, 2024)_(9819993229)_(Springer).pdf

This book introduces different Rare Genetic Disorders (RGDs), and challenges in their diagnosis. The chapters of the book discuss the emerging research and clinical approaches for the diagnosis of rare genetic disorders. It further reviews the future of genetic therapies for the treatment of rare genetic diseases and examine the recent advancements in the field of genetic testing for the diagnosis of these diseases. The book also covers the role of variants in the genome (genetic modifiers) that alleviate (suppress) or exacerbate (enhance) the severity of the disease, resulting in the variability of phenotypic outcomes. Further, the book examines different animal models for critical understanding of disease mechanisms, and the opportunity to evaluate the effect of therapeutic compounds in pre-clinical studies. The subsequent chapters present the state-of-the-art drug discovery strategies and biological approaches for the treatment of rare genetic disorders. Towards the end, the book reviews the current challenges in the diagnosis and treatment of the patients of rare genetic disorders and future opportunities. This book is useful for clinical geneticists, molecular and biochemical geneticists, researchers working in gene therapy and genome editing. Preface Contents About the Editors and Contributors About the Editors Contributors 1: Introduction to Rare Genetic Disorders 1.1 Aarskog Syndrome 1.1.1 Signs and Symptoms 1.1.2 Causes 1.1.3 Diagnosis 1.1.4 Treatment 1.2 Acromesomelic Dysplasia 1.2.1 Signs and Symptoms 1.2.2 Causes 1.2.3 Diagnosis 1.2.4 Treatment 1.3 Acute Eosinophilic Pneumonia 1.3.1 Signs and Symptoms 1.3.2 Causes 1.3.3 Diagnosis 1.3.4 Treatment 1.3.5 Banti Syndrome 1.3.6 Signs and Symptoms 1.3.7 Causes 1.3.8 Diagnosis 1.3.9 Treatment 1.4 Buerger’s Disease 1.4.1 Signs and Symptoms 1.4.2 Causes 1.4.3 Diagnosis 1.4.4 Treatment 1.5 Chronic Lymphocytic Leukaemia 1.5.1 Signs and Symptoms 1.5.2 Causes 1.5.3 Diagnosis 1.5.4 Treatment 1.6 Cicatricial Alopecias 1.6.1 Signs and Symptoms 1.6.2 Causes 1.6.3 Diagnosis 1.6.4 Treatment 1.7 Encephalocele 1.7.1 Signs and Symptoms 1.7.2 Causes 1.7.3 Diagnosis 1.7.4 Treatment 1.7.4.1 Adrenoleukodystrophy 1.7.4.2 Ehlers-Danlos Syndrome 1.7.4.3 Clinical Manifestation 1.7.4.4 Diagnosis 1.7.4.5 Treatment 1.7.5 Usher Syndrome 1.7.6 Alpha-Hydroxylase Deficiency 1.7.7 17-Beta-Hydroxysteroid Dehydrogenase X (17β-HSDX) Deficiency 1.7.8 Beta-Hydroxysteroid Dehydrogenase X (17-HSDX) Deficiency 1.7.9 Achondrogenesis 1.7.10 RPC1B Deficiency 1.7.11 Bamforth-Lazarus Syndrome (BLS) 1.7.12 Bare Lymphocyte Syndrome (BLS) Type I 1.7.13 Regenerate Response 1.7.14 Cantú Syndrome 1.7.15 Combined Oxidative Phosphorylation Deficiency (COXPD) 1.8 Conclusion References 2: Techniques for the Diagnosis of Rare Genetic Disorders 2.1 Introduction 2.2 Rare Genetic Disease 2.3 Standard Classifications of Genetic Testing 2.3.1 Newborn Screening Test 2.3.2 Carrier Testing 2.3.3 Prenatal Diagnostic Testing 2.3.4 Predictive or Predisposition Test 2.3.5 Pharmacogenetic Testing 2.3.6 Ancestry Testing 2.3.7 Paternity Testing 2.3.8 Forensic Testing 2.4 Cytogenetic Testing 2.4.1 Karyotyping 2.4.2 Fluorescence In Situ Hybridization 2.4.3 Comparative Genomic Hybridization 2.4.4 Chromosomal Microarray Analysis (CMA) 2.5 Molecular Testing 2.5.1 Polymerase Chain Reaction (PCR) 2.5.2 Next-Generation Sequencing 2.5.3 Whole-Exome Sequences and Whole-Genome Sequences 2.5.4 CRISPR-Cas9 2.6 Future Prospectives and Conclusion References 3: Prenatal Screening and Counseling for Rare Genetic Disorders 3.1 Introduction 3.1.1 Genetic Counseling 3.2 The Role of Genetic Counseling for Rare Diseases 3.2.1 Prenatal Genetic Counseling 3.2.2 Preconception Genetic Counseling 3.3 Genetic Testing for Rare Diseases 3.3.1 Sanger Sequencing 3.3.2 Next-Generation Sequencing 3.3.3 MS-MLPA 3.3.4 Chromosomal Microarray 3.3.5 Genetic Counselors and Genetic Testing 3.4 Carrier Screening 3.5 Prenatal Diagnosis to Prevent Rare Diseases 3.5.1 Amniotic Fluid 3.5.2 Chorionic Villus Sampling (CVS) 3.5.3 Cord Blood Genetic Evaluation 3.5.4 When and How Should Cordocentesis Be Performed? 3.5.5 Complications 3.5.6 Anomaly Scanning 3.6 Genetic Counseling for Uncommon Diseases: Current Requirements and Future Directions 3.7 Conclusion References 4: Disease Models for Rare Genetic Disorders 4.1 Rare Diseases: An Overview 4.1.1 Prevalence and Classification 4.1.2 Challenges in Diagnosis and Treatment 4.1.3 Impact on Patients and Families 4.1.4 Importance of Research and Future Directions 4.1.4.1 Defining Rare Diseases and Their Challenges Characteristics of Rare Diseases Challenges in Rare Disease Research 4.1.4.2 Understanding the Need for Animal Models Animal Models in Rare Diseases Substantiating the Role of Animal Models in Rare Disease Research Understanding Disease Mechanisms Evaluating Therapeutic Approaches Investigating Disease Progression Drug Discovery and Development 4.2 Choosing and Developing Animal Models 4.2.1 Factors Influencing Model Selection 4.2.2 Developing Animal Models 4.2.2.1 Criteria for Selecting Animal Models 4.2.2.2 Translational Considerations in Model Development 4.2.2.3 Genetic Modification Techniques for Model Creation 4.3 Animal Models Used for Rare Disease Research 4.3.1 Rodent Models for Rare Diseases 4.3.1.1 Advantages of Rodent Models 4.3.1.2 Examples of Rodent Models for Rare Diseases 4.3.1.3 Mouse Models 4.3.1.4 Advantages of Mouse Models 4.3.1.5 Limitations of Mouse Models 4.3.1.6 Rat Models 4.3.1.7 Advantages of Rat Models 4.3.1.8 Applications of Rat Models in Rare Disease Research 4.3.2 Non-rodent Animal Models 4.3.2.1 Advantages of Non-rodent Animal Models 4.3.2.2 Non-rodent Animal Models Used in Research 4.3.2.3 Applications of Non-rodents in Rare Disease Research 4.3.2.4 Primate Models 4.3.2.5 Advantages of Primate Models 4.3.2.6 Applications of Primate Models in Rare Disease Research 4.3.2.7 Canine Models 4.3.2.8 Advantages of Canine Models 4.3.2.9 Applications of Canines in Rare Disease Research 4.3.2.10 Feline Models 4.3.2.11 Advantages of Feline Models 4.3.2.12 Applications of Feline Models in Rare Disease Research 4.3.2.13 Porcine Models 4.3.2.14 Advantages of Porcine Models 4.3.2.15 Applications of Porcine Models in Rare Disease Research 4.3.2.16 Zebrafish Models 4.3.2.17 Advantages of Zebrafish Models 4.3.2.18 Applications of Zebrafish in Rare Disease Research 4.3.2.19 Drosophila Models 4.3.2.20 Advantages of Drosophila Models 4.3.2.21 Applications of Drosophila Models in Rare Disease Studies 4.4 Advancements in Genetic Engineering for Models 4.4.1 CRISPR-Cas9 Technology 4.4.2 Gene Knockout and Knock-In 4.4.3 Conditional and Tissue-Specific Expression 4.4.4 Gene Editing in Induced Pluripotent Stem Cells (iPSCs) 4.4.5 Viral Vectors for Gene Delivery 4.4.6 CRISPR-Based Functional Genomics 4.4.6.1 CRISPR-Cas9 Technology in Model Creation CRISPR-Cas9 Technology Applications of CRISPR-Cas9 Technology in Model Creation Precise Editing and Disease Modeling Accelerated Model Development Gene Knockout and Knock-In: Precision Tools in Genetic Manipulation Gene Knockout Applications of Gene Knockout Gene Knock-In Applications of Gene Knock-In Conditional and Tissue-Specific Expression Conditional Gene Expression Applications of Conditional Gene Expression Tissue-Specific Expression Applications of Tissue-Specific Expression 4.4.6.2 Induced Pluripotent Stem Cells (iPSCs) and Disease Modeling iPSCs Applications of iPSCs in Disease Modeling Limitations and Challenges of iPSCs Future Directions of iPSCs 4.5 Characterizing and Phenotyping Rare Disease Models 4.5.1 Characterization of Rare Disease Models 4.5.2 Phenotyping Rare Disease Models 4.5.3 Significance of Characterization and Phenotyping 4.5.3.1 Behavioral and Physiological Assessments Behavioral Assessments Physiological Assessments Significance of Behavioral and Physiological Assessments 4.5.3.2 Molecular and Histopathological Analyses Molecular Analyses Histopathological Analyses Significance of Molecular and Histopathological Analyses 4.6 Modeling Specific Rare Diseases 4.6.1 Understanding Disease Pathology 4.6.2 Advancing Therapeutic Strategies 4.6.3 Case Examples 4.6.3.1 Neurological Rare Diseases: Model Development and Insights Importance of Animal Models for Neurological Rare Diseases Insights Gained from Neurological Rare Disease Models Challenges and Future Directions 4.6.3.2 Genetic Metabolic Disorders: Animal Models for Mechanistic Studies Importance of Animal Models for Genetic Metabolic Disorders Insights Gained from Genetic Metabolic Disorder Models Challenges and Future Directions 4.6.3.3 Rare Cancers: Animal Models for Therapeutic Exploration Importance of Animal Models for Rare Cancers Insights Gained from Rare Cancer Models Challenges and Future Directions 4.7 In Vivo Imaging and Analysis 4.7.1 Importance of In Vivo Imaging and Analysis 4.7.2 Applications of In Vivo Imaging and Analysis 4.7.3 Advancements and Future Directions 4.7.3.1 Noninvasive Imaging Techniques for Longitudinal Studies Importance of Noninvasive Imaging Techniques for Longitudinal Studies Applications of Noninvasive Imaging Techniques for Longitudinal Studies Advancements and Future Directions 4.7.3.2 Imaging Modalities for Tracking Disease Progression Importance of Imaging Modalities for Tracking Disease Progression Applications of Imaging Modalities for Tracking Disease Progression Advancements and Future Directions 4.8 Therapeutic Approaches and Testing 4.8.1 Importance of Therapeutic Approaches and Testing 4.8.2 Applications of Therapeutic Approaches and Testing 4.8.3 Advancements and Future Directions 4.8.3.1 Preclinical Drug Testing Using Animal Models Importance of Preclinical Drug Testing Using Animal Models Applications of Preclinical Drug Testing Using Animal Models Advancements and Future Directions 4.8.3.2 Gene Therapy Trials in Rare Disease Models Importance of Gene Therapy Trials in Rare Disease Models Applications of Gene Therapy Trials in Rare Disease Models Advancements and Future Directions 4.9 Ethical Considerations and Alternatives in Animal Research 4.9.1 Ethical Considerations in Animal Research 4.9.2 Alternatives to Animal Research 4.9.3 Ethical Dilemmas and Future Directions 4.9.3.1 Ethical Guidelines in Animal Research Importance of Ethical Guidelines in Animal Research Applications of Ethical Guidelines in Animal Research Challenges and Future Directions 4.9.3.2 In Vitro and Computational Models as Alternatives The Significance of In Vitro and Computational Models Applications of In Vitro and Computational Models Advancements and Future Directions 4.10 Case Studies: Successful Applications of In Vitro and Computational Models 4.10.1 Advancements and Future Directions 4.10.1.1 Model-Based Insights Leading to Therapeutic Breakthroughs Understanding Disease Mechanisms Enhancing Drug Discovery Tailoring Personalized Treatments Advancements and Future Directions 4.10.1.2 Collaborative Efforts Between Researchers and Clinicians Advancing Translational Medicine Examples of Collaborative Success 4.11 Challenges and Future Directions 4.11.1 Challenges in Collaborative Research 4.11.2 Future Directions for Effective Collaboration 4.11.3 Ethical Considerations 4.11.3.1 Bridging the Gap Between Animal Models and Human Therapies Challenges in Translating Animal Studies to Human Therapies Strategies for Improved Translational Success Integrated Research-Education Framework 4.11.3.2 Emerging Technologies and Their Impact on Rare Disease Modeling CRISPR-Cas9 and Precision Genome Editing Organ-on-Chip and 3D Culture Systems Advanced Imaging Techniques Omics Technologies Bioinformatics and Computational Modeling 4.12 Regulatory Landscape and Translation to Clinical Trials 4.12.1 Regulatory Challenges in Rare Disease Clinical Trials 4.12.2 Translational Strategies for Clinical Trials 4.12.3 Regulatory Pathways for Rare Disease Therapies 4.12.4 Data Collection and Patient Registries 4.12.5 Global Harmonization and Collaborations 4.12.5.1 FDA and EMA Guidelines for Rare Disease Therapies FDA Guidelines for Rare Disease Therapies EMA Guidelines for Rare Disease Therapies Harmonization and Collaborative Efforts Patient-Centric Approaches 4.12.5.2 Moving from Bench to Bedside: Clinical Trial Considerations Patient Recruitment and Study Design Clinical Endpoint Selection Trial Design and Statistical Considerations Ethical Considerations and Patient Safety Patient Engagement and Advocacy 4.13 Collaborative Networks and Data Sharing in Rare Disease Research 4.13.1 Importance of Collaborative Networks 4.13.2 Benefits of Data Sharing 4.13.3 Challenges and Overcoming Barriers 4.13.4 Successful Collaborative Models 4.13.4.1 Rare Disease Research Consortia: Advantages and Achievements Advantages of Rare Disease Research Consortia Achievements of Rare Disease Research Consortia Therapeutic Development Patient Advocacy and Engagement 4.13.4.2 Data Repositories and Open Science Initiatives in Rare Disease Research Advantages of Data Repositories and Open Science Initiatives Contributions to Rare Disease Research Promotion of Open Science Challenges and Future Directions 4.14 Conclusion 4.14.1 Key Takeaways 4.14.2 The Future of Rare Disease Research 4.14.2.1 Summing Up Contributions and Insights Significant Contributions Key Insights Future Directions 4.14.2.2 Looking Ahead: Unveiling the Potential of Future Research Genomic Precision and Personalized Medicine Advanced Imaging and Functional Characterization Translational Advances and Clinical Impact Ethics and Responsible Research References 5: Research and Clinical Approaches to Undiagnosed Rare Genetic Disorders 5.1 Introduction 5.2 Ethical Considerations in Undiagnosed Rare Diseases 5.3 Challenges Faced by Undiagnosed Rare Disease Patients 5.3.1 Lack of Healthcare Access 5.3.2 Difficulty in Diagnostic Result Interpretation 5.3.3 Current Diagnostic Paradigm 5.3.4 Challenges in Rare Disease Research 5.4 Clinical Approaches to Undiagnosed Rare Diseases 5.5 Diagnosis of Undiagnosed Rare Diseases 5.6 Advances in Research on Undiagnosed Rare Diseases 5.6.1 Multi-Omics Approach 5.6.2 Role of Artificial Intelligence (AI) in URD Research 5.6.3 Understanding Disease Mechanisms in Model Organisms 5.7 Rare Disease Registries 5.8 Patient Match-Making Exchanger 5.9 Collaborative Networks 5.10 Research Gaps in URDs 5.11 Research Funds and Policies 5.12 Management of URDS 5.13 Therapies for URDs 5.14 Conclusion and Future Direction References 6: Drug Discovery and Development for Rare Genetic Disorders 6.1 Introduction 6.2 Etiology 6.3 Challenges in Rare Disease Treatment 6.4 Treatment Options for Genetic Disorders 6.5 Identification of Target Molecules 6.6 Bioassay Development 6.7 Compound Library 6.8 Virtual Screening 6.9 Experimental Screening 6.10 Hit Confirmation 6.11 Lead Generation and Optimization 6.12 Preclinical Studies 6.13 Drug Pharmacokinetics 6.14 Drug Formulation 6.15 Human Clinical Trials 6.16 Drug Registration and Pharmacovigilance 6.17 Drug Repositioning 6.18 Biologics 6.19 Future Prospective 6.20 Conclusion References 7: Rare Genetic Disorders: Unraveling the Pathophysiology, Gene Mutations, and Therapeutic Advances in Fabry Disease and Marfan Syndrome 7.1 Introduction 7.2 Methods 7.3 Fabry Disease 7.3.1 History and Occurrence 7.3.2 Gene Mutations 7.3.3 Therapeutics 7.4 Marfan Syndrome 7.4.1 History and Occurrence 7.4.2 Gene Mutation 7.4.3 Therapeutics 7.5 Conclusion References 8: Current Insights into the Potential of Gene Therapy to Treat Rare Mitochondrial Diseases 8.1 Introduction 8.2 Mitochondrial Genome and Organization 8.2.1 Replicative Segregation 8.2.2 Heteroplasmy and Homoplasmy 8.2.3 Maternal Inheritance 8.3 Mutations in Mitochondrial DNA 8.4 Diagnosis and Screening of Mitochondrial Diseases 8.4.1 Molecular Diagnostics 8.5 Mitochondrial Diseases 8.5.1 Leber Hereditary Optic Neuropathy (LHON) 8.5.2 Friedreich’s Ataxia (FRDA) 8.5.3 Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) 8.5.4 Alpers Disease 8.5.5 Leigh’s Disease 8.6 Gene Therapies to Treat MD 8.6.1 Viral Based Approaches 8.6.1.1 Friedrich Ataxia 8.6.1.2 Leigh’s Disease 8.6.1.3 Leber Hereditary Optic Neuropathy (LHON) 8.6.2 Non-viral Approaches 8.6.2.1 Mitochondrial Replacement Therapy (MRT) 8.6.2.2 Allotopic Expression 8.6.3 Genome Editing Tools 8.6.3.1 Zinc Finger Nucleases (ZFNs) and Transcription Activator-Like Effector Nucleases (TALENs) 8.6.3.2 CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) 8.7 Translational Perspectives and Challenges References 9: Challenges and Future Opportunities in Rare Genetic Disorders: A Comprehensive Review 9.1 Introduction 9.2 Methods 9.3 Challenges 9.3.1 Limited Understanding and Research 9.3.2 Diagnostic Delays 9.3.3 Therapeutic Challenges 9.3.4 Patient Access to Treatment 9.3.4.1 Unavailability of Treatment 9.3.4.2 Treatment Costs That Are Out of Reach 9.3.5 Collaboration and Information Sharing 9.4 Future Opportunities 9.4.1 Improved Genomic Technologies 9.4.2 Precision Medicine 9.4.3 Drug Repurposing 9.4.4 Advocacy and Patient Empowerment 9.4.5 Regulatory Incentives 9.4.6 Information Sharing and Global Cooperation 9.5 Discussion and Conclusion 9.6 Planning for the Care of Rare Disorders References